CNS & Neurological Disorders - Drug Targets

Author(s): David Calderón Guzmán, Norma Osnaya Brizuela, Maribel Ortíz Herrera, Hugo Juárez Olguín*, Armando Valenzuela Peraza, Ernestina Hernández García, Francisca Trujillo Jiménez and Gerardo Barragán Mejía

DOI: 10.2174/1871527318666181128144343

DownloadDownload PDF Flyer Cite As
Cytarabine and Ferric Carboxymaltose (Fe+3) Increase Oxidative Damage and Alter Serotonergic Metabolism in Brain

Page: [149 - 155] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background & Objective: The purpose of this study was to measure the effect on brain biomarkers after treatment with anticancer compounds - cytarabine (CT) and ferric carboxymaltose (FC) (Fe+3) in Wistar rats.

Methods: The Wistar rats were treated as follows: group 1 (control), NaCl 0.9%; group 2, CT (25 mg/k), group 3, FC(Fe+3) (50 mg/k) and group 4, CT + FC(Fe+3). The animals were sacrificed and their brains were obtained and used to measure lipoperoxidation (TBARS), H2O2, Na+, K+ ATPase, glutathione (GSH), serotonin metabolite (5-HIAA) and dopamine. The results indicated an enhancement of lipid peroxidation in the cortex and striatum of groups treated with FC(Fe+3) and CT, while GSH decreased in the cortex of group treated with CT + FC(Fe+3). Dopamine decreased in the cortex of the rats that received CT, while in the striatum, 5HIAA increased in all groups.

Results & Conclusion: These results suggest that the treatment with CT and FC(Fe+3) boosted oxidative stress and led to an alteration in momoamine concentrations in the brain.

Keywords: Iron, oxidative damage, brain, anticancer agents, oncological diseases, malignant tumor.